News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Watson Pharmaceuticals, Inc. (WPI) at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top



12/20/2012 9:38:49 AM

PARSIPPANY, N.J., Dec. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top conference on Thursday, January 3, 2013 at 1:45 pm EST at the Goldman Sachs Conference Center in New York. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Web site at http://ir.watson.com.  The webcast can also be accessed at the following URL:

http://cc.talkpoint.com/gold006/010313a_gm/?entity=1_434SLG2

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

Watson is the world's third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries.  Watson's global branded pharmaceutical business develops and markets products principally in Urology and Women's Health, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories.  In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.  Watson has announced that it will adopt a new global name Actavis   effective in 2013.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

CONTACTS:

Investors:


Lisa DeFrancesco


(862) 261-7152




Media:


Charlie Mayr


(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES